Immunotherapy desensitization protocols consist of an induction phase with increasing dosages followed by repeated maintenance doses.
Is it true that immunotherapy desensitization protocols consist of an induction phase with increasing dosages followed by repeated maintenance doses?
Yes. Immunotherapy desensitization protocols generally begin with an escalation or induction phase using gradually increasing dosages before transitioning to repeated maintenance doses.
Verdict: SUPPORTED · 5 sources for, 0 against · Last checked
The claim accurately describes the standard protocol for allergen immunotherapy (both subcutaneous and oral/sublingual), which involves an initial build-up or induction phase with escalating doses followed by a maintenance phase. Multiple retrieved clinical studies and guidelines (such as [0], [1], [2], [3], and [5]) explicitly detail this standard two-phase structure (updosing/escalation followed by maintenance).
Get citation
F, R., A, B., S, B., R, B., K, B., AM, C., U, D., J, F., T, F., M, G., S, G., E, H., W, H., L, K., L, L., H, M., NK, M., I, N., W, P., W, S., H, S., C, S., R, T., B, W., S, W., M, W., & T, J. (2023). Diagnosis and treatment of Hymenoptera venom allergy: S2k Guideline of the German Society of Allergology and Clinical Immunology (DGAKI) in collaboration with the Arbeitsgemeinschaft für Berufs- und Umweltdermatologie e.V. (ABD), the Medical Association of German Allergologists (AeDA), the German Society of Dermatology (DDG), the German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNOKC), the German Society of Pediatrics and Adolescent Medicine (DGKJ), the Society for Pediatric Allergy and Environmental Medicine (GPA), German Respiratory Society (DGP), and the Austrian Society for Allergy and Immunology (ÖGAI).. doi.org. https://doi.org/10.5414/alx02430e
See more details
Get citation
H, H., KL, U., V, C., CC, Y., I, T., O, T., J, L., LQC, S., C, V., MH, S., & SJ, T. (2025). Oral Immunotherapy in Peanut-Allergic Adults Using Real-World Materials.. doi.org. https://doi.org/10.1111/all.16493
Get citation
Jung, K. (2011). Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio. doi.org. https://doi.org/10.1111/j.1398-9995.2011.02632.x
Get citation
Jourdy, D. N. & Reisacher, W. R. (2012). Factors affecting time required to reach maintenance dose during subcutaneous immunotherapy. doi.org. https://doi.org/10.1002/alr.21027
Get citation
M, J., M, P., E, P., E, H., A, K., M, E., L, H., SK, G., EI, C., & LO, C. (2025). Subcutaneous Allergen-Specific Immunotherapy for Allergic Rhinitis: Divergent IgA Responses in Nasal Mucosa and Blood With Validation of B Cell Class-Switching in Lymph Nodes and Blood.. doi.org. https://doi.org/10.1002/clt2.70097
What does the evidence say?
The claim accurately describes the standard protocol for allergen immunotherapy (both subcutaneous and oral/sublingual), which involves an initial build-up or induction phase with escalating doses followed by a maintenance phase. Multiple retrieved clinical studies and guidelines (such as [0], [1], [2], [3], and [5]) explicitly detail this standard two-phase structure (updosing/escalation followed by maintenance).
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work